Cancer Cell Panel Screening, a platform involving the screening of test agents on cells with diverse genomic backgrounds, has emerged as a comprehensive tool for oncology therapeutic development. It provides critical insights into the identification of cell lines that exhibit high sensitivity to certain test agents, the exploration of drug mechanisms, and the evaluation of the efficacy of combination therapies.
☑️ Comprehensive Cancer Cell Line Selection: Access 600+ cancer cell lines, including 100+ engineered KO, KI, and drug-resistant lines. Specialized panels for DNA repair & Synthetic Lethality targets available.
☑️ 2D and 3D Viability Assays and Diverse Assay Offerings: Measure cell viability with 2D/3D CellTiter-Glo®. Includes colony formation, cell cycle analysis, apoptosis studies, and combination studies with no timeline restrictions.
☑️ RNA-Seq and Advanced Bioinformatics: Gain insights into drug response and resistance mechanisms through RNA sequencing and advanced bioinformatics analysis.
☑️ In Vivo CDX Models: Seamlessly transition to in vivo studies using CDX models derived from these cell lines.
Plate Formats: 96-well plate / 384-well plate
Assay Formats: CellTiter-Glo, CyQUANT, Hoechst, Ki67
Assay Conditions: 10% FBS or 2%-5% FBS (serum concentration)
Number of Doses: 10 doses (IC50 or GI50 format)
Number of Replicates: Duplicate
Compound Treatment Duration:
- 3 days, 5 days, 7 days, or extended time
- At least 2 cell doubling times
- Custom durations based on client preferences
Comprehensive Documentation: Detailed methods and testing conditions
Quality Control Metrics: Z' factor, Signal-to-Window (SW), Coefficient of Variation (CV%), Reference compound data
Experimental Results: % Inhibition, curve fitting, and IC50 values (calculated using XLfit or GraphPad Prism, if applicable)
- Combination Studies
- Target Engagement Assays
- Cell Apoptosis Assays, Cell Cycle Analysis, Protein Phosphorylation Assays
- Xenograft Models
Choose from over 500 human tumor cell lines available in our ICE cell bank, with an ongoing addition of cell lines per month. Collaborators have the flexibility to select specific cell lines of interest from our cell bank to create a tailored Cell Panel for screening.
ICE Bioscience has established a predefined cell panel comprising 170 tumor cell lines, covering 21 cancer types. This cell panel can be utilized for screening sensitive cell lines against test agents, exploring new drug indications, and conducting toxicity screening. ICE also has a bioinformatics team and a cell line information database to support both early- and late-stage bioinformatics analyses of the cell panel.
Our bioinformatic analysis of drug-resistant cell lines based on RNA-seq. Using our internal algorithms, we can provide detailed differential gene expression information, enrichment pathways, and characteristic gene profiles.
Our specialized panels include targeting DDR, RAS, EGFR, and HER2 cell lines. These panels are designed to facilitate mechanism of action studies, and drug sensitivity testing, providing powerful tools to accelerate therapeutic development.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
